지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Patients with hyperglycemia are at a high risk of cardio- and cerebrovascular diseases. Diabetes patients also have poor outcomes after cerebrovascular disease development. Several classes of drugs are used for diabetes management in clinical practice. Thiazolidinedione (TZD) was introduced in the late 1990s, and new antidiabetic agents have been introduced since 2000. After issues with rosiglitazone in 2007, the U.S. Food and Drug Administration strongly recommended that trials investigating cardiovascular risk associated with new antidiabetic medications should be conducted before drug approval in the United States, to prove the safety of these new drugs and to determine their superiority to previous medications. Currently, results are available from two studies with TZD focusing on cardiovascular diseases, including stroke, and from 12 cardiovascular outcome trials focusing on major adverse cardiovascular events associated with new antidiabetic agents (four with dipeptidyl peptidase-4 inhibitors, three with sodium-glucose cotransporter-2 inhibitors, and five with glucagon-like peptide-1 analogues). These studies showed different results for primary cardiovascular outcomes and stroke prevention. It is important to determine whether prescription of TZD or new antidiabetic medications compared to conventional treatment, such as sulfonylurea or insulin, is better for stroke management. Furthermore, it is unclear whether drugs in the same class show greater safety and efficacy than other drugs for stroke management.
목차
등록된 정보가 없습니다.
참고문헌 (84)
참고문헌 신청
Gaede P / 2008 / Effect of a multifactorial intervention on mortality in type 2 diabetes / N Engl J Med 358:580~591
Yang Y / 2013 / Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese / Diabetes Care 36:978~984
Griffin SJ / 2011 / Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe):a cluster-randomised trial / Lancet 378:156~167
Stead LG / 2009 / Hyperglycemia as an independent predictor of worse outcome in non-diabetic patients presenting with acute ischemic stroke / Neurocrit Care 10:181~186
Emerging Risk Factors Collaboration / 2010 / Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies / Lancet 375:2215~2222
Yang Y / 2013 / Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese / Diabetes Care 36:978~984
Griffin SJ / 2011 / Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe):a cluster-randomised trial / Lancet 378:156~167
Stead LG / 2009 / Hyperglycemia as an independent predictor of worse outcome in non-diabetic patients presenting with acute ischemic stroke / Neurocrit Care 10:181~186
Emerging Risk Factors Collaboration / 2010 / Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies / Lancet 375:2215~2222
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
당뇨병 치료약제와 심혈관 질환
대한내과학회지
2021 .04
-
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2022 .07
-
Diabetes Drugs and Cardiovascular Safety
Endocrinology and Metabolism
2016 .01
-
Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?
Journal of Obesity & Metabolic Syndrome
2017 .01
-
Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism
지질·동맥경화학회지
2018 .01
-
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Diabetes and Metabolism Journal
2024 .03
-
Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
대한골대사학회지
2024 .08
-
새로운 당뇨병 치료제
대한의사협회지
2017 .01
-
Medicinal plants and phytochemicals for diabetes mellitus: pharmacokinetic characteristics and herb‑drug interactions
Journal of Pharmaceutical Investigation
2019 .01
-
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2021 .01
-
Diabetes and Stroke: What Are the Connections?
대한뇌졸중학회지
2023 .01
-
The Current Status of New Antidiabetic Drugs
Journal of Pharmacopuncture
2016 .12
-
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Clinical and Molecular Hepatology
2022 .07
-
Professional Continuous Glucose Monitoring Reveals Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Treated with Oral Antidiabetics
Korean Journal of Family Medicine
2021 .01
-
간호대학생의 의약품 자가투약 실태, 약물에 대한 지식 및 태도에 관한 연구
의료커뮤니케이션
2018 .01
-
노인 심혈관질환의 다약제 포괄관리
대한의사협회지
2024 .07
-
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World- Based Cohort Study (Diabetes Metab J 2019;43:640-8)
Diabetes and Metabolism Journal
2019 .01
-
Executive Summary of Stroke Statistics in Korea 2018: A Report from the Epidemiology Research Council of the Korean Stroke Society
대한뇌졸중학회지
2019 .01
-
의약품 정보 제공 용어의 이해도 평가: 당뇨 및 천식 처방약과 안전상비약을 중심으로
대한보건연구
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0